Long‑term use of uric‑acid‑lowering drugs after a gout diagnosis to keep levels below 360 µmol/L

Cost: Allopurinol costs only a few to several tens of yuan per month. At first, blood uric‑acid levels must be checked every few weeks to adjust the dose; once stable, checks can be done every few months. For the first 3–6 months, a second medication to prevent flare‑ups is also required. The difficulty lies in the fact that patients must keep taking it even when they feel no pain.

In plain terms: Gout requires lifelong use of uric‑acid‑lowering drugs to keep levels under 360 µmol/L; painkillers alone are insufficient. In a study where nurses helped patients adjust their dose based on lab results, 95 % reached the target after two years, compared with only 30 % of patients seen by regular doctors. Even after reaching the target, medication must not be stopped. Diet changes alone cannot bring levels down to this point, and abstaining from alcohol lowers them by just 1.6 mg/dL.

Benefit: In a randomized controlled trial of 517 adults who had experienced gout attacks within the previous 12 months, one group received nurse‑led education and dose adjustments to achieve the target level, while the other continued routine care. After two years, 95 % of the intervention group versus 30 % of the control group had uric‑acid levels below 360 µmol/L (6 mg/dL). The odds of success were 3.18 times higher in the intervention group (RR 3.18, 95 % CI 2.42–4.18; P < 0.0001). Secondary outcomes — attack frequency, tophus formation, and quality of life — also improved. Each additional quality‑adjusted life year gained cost £5,066. Follow‑up data showed that 82 % of participants reported zero attacks in the previous year, versus a median of one attack for the control group (P < 0.001). The proportion still on therapy was 1.19 times higher in the intervention group (adjusted RR 1.19, 1.09–1.30). The 2020 American College of Rheumatology guidelines recommend uric‑acid‑lowering therapy for patients with tophi, bone erosion on imaging, or ≥2 attacks per year; the target is <6 mg/dL, achieved by regular monitoring and dose titration, with allopurinol as first‑line therapy, especially for those with stage 3 or higher chronic kidney disease. Anti‑inflammatory prophylaxis is advised for 3–6 months at initiation. Observational data indicate that after successful control, many patients can discontinue medication without relapse; however, only 13 % remained flare‑free over five years. Alcohol restriction lowers uric‑acid levels by 1.6 mg/dL, while a single beer raises them by 0.16 mg/dL; healthier diets have far smaller effects. Debate persists over optimal drug choice: allopurinol is favored for its efficacy, safety, and low cost, though patients with cardiovascular disease or recent events may be switched to other agents per FDA warnings. The CARES trial linked allopurinol to a 22 % higher risk of all‑cause mortality (HR 1.22) and a 34 % higher risk of cardiovascular death (HR 1.34) versus allopurinol; the European FAST trial found no such increase. Urine alkalinization is not recommended for uricosuric agents due to lack of evidence. Adequate hydration is essential, especially for patients with kidney stones or advanced CKD.

Evidence grade: A

Sources:Doherty M, Jenkins W, Richardson H, et al. (2018). Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet, 392(10156), 1403-1412. https://doi.org/10.1016/S0140-6736(18)32158-5；Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M (2020). Nurse-led care is preferred over GP-led care of gout and improves gout outcomes: results of Nottingham Gout Treatment Trial follow-up study. Rheumatology, 59(3), 575-579. https://doi.org/10.1093/rheumatology/kez333；FitzGerald JD, Dalbeth N, Mikuls T, et al. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research, 72(6), 744-760. https://doi.org/10.1002/acr.24180；White WB, Saag KG, Becker MA, et al.; CARES Investigators (2018). Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine, 378(13), 1200-1210. https://doi.org/10.1056/NEJMoa1710895；Mackenzie IS, Ford I, Nuki G, et al.; FAST Study Group (2020). Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 396(10264), 1745-1757. https://doi.org/10.1016/S0140-6736(20)32234-0；中华医学会内分泌学分会 (2020). 中国高尿酸血症与痛风诊疗指南(2019). 中华内分泌代谢杂志, 36(1), 1-13. https://doi.org/10.3760/cma.j.issn.1000-6699.2020.01.001

Notes: Controversy exists: different countries recommend different first‑line drugs. The U.S. guideline favors allopurinol and advises avoiding febuxostat in patients with cardiovascular disease, whereas the FAST trial found no increased risk with febuxostat. Probenecid, another uricosuric agent, is available in China. Chinese guidelines (2019 and 2024 updates) provide separate recommendations on drug selection and urine alkalinization; they suggest that sodium bicarbonate may be unnecessary, but hydration remains crucial. Han Chinese individuals should be screened for HLA‑B*5801 before starting allopurinol; carriers account for 7.4 % of Han Chinese, 0.7 % of Caucasians and Hispanics, and have a three‑fold higher risk of allopurinol‑induced hypersensitivity syndrome, a potentially fatal condition involving extensive skin peeling. The 2020 ACR guidelines recommend screening for these groups. Initiation of therapy can temporarily increase flare‑ups, so anti‑inflammatory prophylaxis for 3–6 months is mandatory; discontinuing uric‑acid‑lowering drugs because of pain is a common cause of treatment failure. When an attack occurs, additional anti‑inflammatory medication should be added per medical advice, not the uric‑acid‑lowering drug. Target levels are expressed as <6 mg/dL (≈360 µmol/L); Chinese labs typically report µmol/L. Asymptomatic hyperuricemia is addressed separately in Section 6, Item 19. Sugar‑sweetened beverages and alcohol are discussed in Section 2, Items 7 and 19. 〔100〕 〔100〕 〔438〕 〔211〕 〔6190〕 〔1.01〕 〔1.47〕 〔1.03〕 〔1.03〕 〔1.73〕 〔6128〕 〔60〕 〔0.85〕 〔7.2〕 〔8.6〕